Nguyen, Quynh-Anh https://orcid.org/0000-0003-4910-7899
Klein, Peter M. https://orcid.org/0000-0002-3232-3387
Xie, Cheng
Benthall, Katelyn N.
Iafrati, Jillian
Homidan, Jesslyn
Bendor, Jacob T.
Dudok, Barna https://orcid.org/0000-0001-5078-0090
Farrell, Jordan S. https://orcid.org/0000-0002-1209-5559
Gschwind, Tilo
Porter, Charlotte L. https://orcid.org/0009-0009-9750-9148
Keravala, Annahita
Dodson, G. Steven
Soltesz, Ivan https://orcid.org/0000-0003-1493-3744
Funding for this research was provided by:
CODA Biotherapeutics
Article History
Received: 21 February 2023
Accepted: 9 January 2024
First Online: 18 January 2024
Competing interests
: Q-.A.N., P.M.K., J.H., B.D., J.S.F., T.G., C.L.P. and I.S. declare no competing interests beyond utilizing reagents and funding from CODA Biotherapeutics for the experiments described in the paper. C.X., K.B., J.I., J.T.B., A.K. and G.S.D. were employees of CODA Biotherapeutics. Patent #10538571 has been issued to CODA Biotherapeutics on compositions and methods for modulating the activity of cells using engineered receptors, polynucleotide-encoded engineered receptors, and gene therapy vectors comprising polynucleotides encoding engineered receptors.